Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 5, 2026Discover Pharmaceutical SciencesOpen Access

Engineered exosome nanocarriers offer targeted drug delivery for CVD despite significant translational challenges.

View Full Paper
Ask AI
Bookmark
Share

Design

Review

Key result

Engineered exosome-based nanocarriers represent a transformative strategy for targeted drug delivery in cardiovascular diseases, though significant translational challenges persist.

Authors

RWRufaida WasimASAditya Singh

Discussion

Loading...

Member takes

Overview

Encourages clinical translation of exosome nanocarriers in CV disease; extends RCT evidence on targeted delivery.

Key Points

  • The aim is to explore engineered exosome-based nanocarriers for effective targeted therapy in cardiovascular diseases.
  • Engineered exosomes were developed using techniques like electroporation and genetic modification.
  • Surface functionalization strategies enhanced targeting capabilities specific to cardiac tissues.
  • Preclinical studies assessed cardioprotective effects and inflammatory responses.
  • Exosome-based therapy showed significant cardioprotective effects in myocardial infarction models.
  • Demonstrated attenuation of inflammation in atherosclerosis and reduced fibrosis in heart failure.
  • Enhanced angiogenesis observed in ischemic injury models.

Structured PICO

I
Intervention
Engineered exosome-based nanocarriers for targeted drug delivery

Engineered exosome-based nanocarriers offer a transformative strategy for targeted cardiovascular drug delivery, but require overcoming significant manufacturing and regulatory barriers for clinical translation.

Limitations

  • Scalable manufacturing
  • Standardization of isolation and purification methods
  • Cargo loading efficiency
  • Storage stability
  • Regulatory classification
  • Long-term biosafety evaluation
  • scalable manufacturing
  • standardization of isolation and purification methods
  • cargo loading efficiency
  • storage stability
  • regulatory classification
  • long-term biosafety evaluation

Cite This Study

Wasim et al. (2026) conducted a review in Cardiovascular diseases. Engineered exosome nanocarriers was evaluated. Engineered exosome-based nanocarriers represent a transformative strategy for targeted drug delivery in cardiovascular diseases, though significant translational challenges persist.

synapsesocial.com/papers/6a49f547f5d1d45b288004echttps://doi.org/10.1007/s44395-026-00048-2
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Multifaceted mechanisms and targeted delivery of mesenchymal stem cell-derived exosomes in cardiovascular diseases: a translational medicine perspective2025 · 1 citations
  2. 2Nanoengineering of Exosomal Surfaces for Precision Targeting and Payload Delivery at the Molecular Level.2025 · 4 citations
  3. 3Prospects of Engineered Exosomes in Clinical Applications: A Review2025 · 11 citations
  4. 4The Application of Engineered Exosomes in Tumour Therapy: Challenges and Prospects from Design to Clinic2025 · 2 citations
  5. 5Clinical insights into extracellular vesicles for targeted myocardial drug delivery2025 · 7 citations